key: cord-0868724-4867otcr
authors: Roussel, Ronan; Darmon, Patrice; Pichelin, Matthieu; Goronflot, Thomas; Abouleka, Yawa; Ait Bachir, Leila; Allix, Ingrid; Ancelle, Deborah; Barraud, Sara; Bordier, Lyse; Carlier, Aurélie; Chevalier, Nicolas; Coffin‐Boutreux, Christine; Cosson, Emmanuel; Dorange, Anne; Dupuy, Olivier; Fontaine, Pierre; Fremy, Bénédicte; Galtier, Florence; Germain, Natacha; Guedj, Anne‐Marie; Larger, Etienne; Laugier‐Robiolle, Stéphanie; Laviolle, Bruno; Ludwig, Lisa; Monier, Arnaud; Montanier, Nathanaëlle; Moulin, Philippe; Moura, Isabelle; Prevost, Gaëtan; Reznik, Yves; Sabbah, Nadia; Saulnier, Pierre‐Jean; Serusclat, Pierre; Vatier, Camille; Wargny, Matthieu; Hadjadj, Samy; Gourdy, Pierre; Cariou, Bertrand
title: Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
date: 2021-02-16
journal: Diabetes Obes Metab
DOI: 10.1111/dom.14324
sha: 47d38dae058c7f583916f1db6e882a5d7e5e6c16
doc_id: 868724
cord_uid: 4867otcr

AIM: To investigate the association between routine use of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and the severity of coronavirus disease 2019 (COVID‐19) infection in patient with type 2 diabetes in a large multicentric study. MATERIALS AND METHODS: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID‐19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP‐4 inhibitors users vs. non‐users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW). RESULTS: Five hundred and ninety‐six participants were under DPP‐4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non‐users of DPP‐4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW‐adjusted models showed no significant association between the use of DPP‐4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77–1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78–1.17]). Similar neutral findings were found between use of DPP‐4 inhibitors and the risk of tracheal intubation and death. CONCLUSIONS: These data support the safety of DPP‐4 inhibitors for diabetes management during the COVID‐19 pandemic and they should not be discontinued.

Diabetes has been evidenced as one of the main clinical factors associated with severity of coronavirus disease 2019 .

Dipeptidyl peptidase-4 (DPP-4 [or CD26]), a transmembrane glycoprotein, expressed in endocrine cells, immune cells, endothelial cells and pneumocytes, among many tissues, is now recognized as a coronavirus receptor protein. 1 Its functions, which are incompletely unveiled, include degradation of incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, but also immune regulation by activation of T cells, upregulation of CD86 expression and NF-kappa B pathway, and cleavage of a number of cytokines, chemokines and growth factors. 2 During previous coronavirus epidemics, it was suggested that higher severity of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in type 2 diabetes (T2D) could be associated with a DPP-4-mediated dysregulated immune response. The hypothesis was supported by experimental work using human-DPP-4-expressing transgenic obese mice, 3 and also by a genetic association study in patients, 4 and has been recently reviewed. [5] [6] [7] On the other hand, administration of recombinant soluble DPP-4 attenuated lung histopathology in another preclinical study. 8 This was consistent with the observation of lower circulating levels of soluble DPP-4 in human subjects with MERS-CoV, relative to healthy controls. 9 People with T2D, whether they are obese or not, are commonly treated with DPP-4 inhibitors. There is no evidence of a higher risk of respiratory tract infections associated with the use of this class of antidiabetic drugs according to randomized controlled trials 10 or observational studies, 11 Thus, discrepant messages have been received by healthcare providers and people with diabetes. To the best of our knowledge, the clinical evidence they need to guide their decisions regarding the use of DPP-4 inhibitors is still limited to a small neutral case control study. 14 Our purpose was to investigate the association between the use of DPP-4 inhibitors and the early severity of illness and mortality in patients with T2D hospitalized for COVID-19 infection, by using propensity score matching in the CORONADO (CORONAvirus and Diabetes Outcomes) study.

The current study was a secondary analysis of the CORONADO study (ClinicalTrials.gov NCT04324736), which aimed to describe the phenotype and prognosis of people with diabetes admitted to hospital for COVID-19 and diabetes from 10 March to 10 15 For the purpose of the current subanalysis, information on the routine use of DPP-4 inhibitors (i.e. sitagliptin, vildagliptin and saxagliptin, which are commercially available in France) prior to admission was mandatory for inclusion.

Clinical and biological data have been described previously. 15 In the current analysis, HbA1c and estimated glomerular filtration rate (eGFR) values correspond to the more recent routine biological determinations in the 6 and 12 months preceding admission, respectively.

The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Secondary outcomes included death on Day 7, tracheal intubation on Day 7, admission to intensive care units and discharge on Day 7. In the population still hospitalized on Day 7, these outcomes were reassessed until Day 28.

Quantitative data are given as mean ± SD or median (25th-75th percentile). Categorical variables are given as number (%) of participants.

Patients were classified into two groups according to the use of DPP-4 inhibitors prior to admission. For between-group comparisons, unpaired t-tests or Wilcoxon rank-sum tests were used for quantitative variables, while Fisher's exact tests were used for categorical variables. For missing values, a multiple imputation by chained equation using R package mice (seven replicates with 'predictive mean matching' and 'logistic regression' methods for respectively continuous and binary variables) was performed. 16 After a careful study of the performance of imputation, replicates were pooled to obtain the complete dataset to conduct multivariable analyses.

To balance the distributions of baseline covariates between groups and then limit confounding bias in analyses, we estimated a propensity score (PS) with a logistic regression model on sex, age, body mass index (BMI), arterial hypertension, history of ischaemic heart disease, history of heart failure, active cancer, treated obstructive sleep apnoea (OSA), and the use of metformin, sulphonylurea, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), insulin, corticosteroids, renin-angiotensin system blockers, statins, thiazide diuretics and antiplatelet therapy. In sensitivity analysis, the following complementary variables were added: eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation, diabetes duration and the latest HbA1c (<6 months prior to admission). For each model, these variables were selected based on their relevance in clinical practice and statistically (p < .15 in univariable association with outcome).

In the PS calculation, we did not include variables that are associated with exposition status but not with the primary endpoint, because this might have had a counterproductive effect by increasing bias and variance in the estimate of treatment effect. 17 Comparability was assessed by analysing the reduction in the standardized mean difference (SMD) after PS utilization. Stabilized weights 18 were computed for patients based on an overlap-weighting method and were used in multivariable logistic regression models to estimate the average treatment effect in the treated (ATT) as inverse probability of treatment weighting (IPTW). 19 In addition, PS was used in Cox models to estimate IPTW hazard ratios (presented in the supporting information).

Proportional hazards assumption was carefully studied. Analyses were performed using R version 3.6.2, in particular the packages PSW, 19 hrIPW 20 and ggplot2 21 to estimate the treatment effect in logistic regression models, in survival models and for figures, respectively.

The study population consisted of 2449 patients with T2D declaring the use of at least one antidiabetic drug prior to hospital admission for COVID-19, and available information on the primary outcome at Day Table 1 . Patients using DPP-4 inhibitors were less frequently women (32.6% vs. 37.1% in non-users; p = .0455), had a lower median BMI, and less frequently a history of severe diabetic retinopathy, peripheral artery disease or non-alcoholic fatty liver disease.

As expected, treatment patterns were strikingly different for antidiabetic but also cardiovascular therapies. DPP-4 inhibitor users were more frequently under metformin and less frequently under GLP-1

RAs or insulin therapy. In addition, they were more frequently under renin-angiotensin-aldosterone system blockers and less frequently under beta blockers. Upon admission, patients under DPP-4 inhibitors appeared to have a slightly more severe form of infection, with higher F I G U R E 1 Study flowchart. CCF, case report form; DPP-4, dipeptidyl peptidase-4 T A B L E 1 Clinical characteristics prior to admission of CORONADO participants according to the use of dipeptidyl peptidase-4 (DPP-4) inhibitors 

The primary outcome (tracheal intubation for assisted mechanical ventilation or death on Day 7 after admission) occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .6765).

The same was true for each component of the primary outcome taken individually (Table S1 ). The pattern was similar when outcomes were reassessed at Day 28, except for a trend of a non-significant reduction in mortality in DPP-4 inhibitor users (18.1% vs. 21.8%; p = .0561) ( Table S1 ).

Because the use of DPP-4 inhibitors and outcomes were significantly associated with some baseline characteristics that can alter the severity of COVID-19, we conducted a PS analysis to balance baseline distributions of age, sex, BMI, history of heart failure, arterial hypertension or ischaemic heart disease, and active cancer, and also regarding treatments for obstructive apnoea, antiplatelet therapy and the use of metformin, insulin, sulphonylurea, renin-angiotensin system blockers, statins, corticosteroids and thiazide diuretics. We performed a multiple imputation for the missing values. As illustrated in Figure 2 , the reduction in SMD after using IPTW in models illustrated the gain in comparability between groups on baseline covariates. The IPTweighted models at Day 7 showed no association between the use of F I G U R E 2 Baseline characteristics balance between dipeptidyl peptidase-4 (DPP-4) inhibitor users and non-users after propensity score use in models as inverse probability of treatment weighting. BMI, body mass index; GLP-1, glucagon-like peptide-1; IPTW, inverse probability of treatment weighting DPP-4 inhibitors and the primary outcome or its individual component, even after further adjustment for kidney function (i.e. eGFR values), diabetes duration and HbA1c (Table 3 ).

In the current study, we report evidence supporting the safety of the In people with diabetes, prior studies suggested a lack of an association between the use of DPP-4 inhibitors and the occurrence of community-acquired pneumopathy from any cause, 12,24 but also specifically because of SARS-CoV-2. 14 Furthermore, recent observations reported either a reduced mortality rate 25, 26 or a neutral effect 27, 28 associated with the use of DPP-4 inhibitors prior to or during hospitalization for COVID-19, in patients with T2D. The literature already includes papers questioning a wide use of the class for preventing COVID-19 and its complications. 29 As thoroughly discussed in a commentary paper, 30 all these studies have strong limitations (some of which were shared by our current work, first of all their observational nature). These limitations were probably balanced by the potential importance of their messages during the editorial process, because of the emergency context of the ongoing pandemic. Calls for randomized trials have been made, but they will take time to be delivered, and the community is in urgent need of more evidence in the meantime.

In the CORONADO study, participants on routine DPP-4 inhibitors showed a few traits at admission presumed to be associated with a severe illness, such as a higher prevalence of fatigue, lower lymphocyte count, higher plasma D-dimer, glucose and CRP concentrations. and also eventually in the reporting of deaths. Therefore, these data were not collected in the current study. However, experimental and further confirmatory epidemiological data are strongly required to validate the hypothesis raised here.

As highlighted before, our study presents some limitations that should be noted. CORONADO is an observational study that collected data from people with diabetes and COVID-19 upon admission across a large number of hospitals in France. As such, it cannot provide insight into the outcomes of COVID-19 in the community. Moreover, it was not feasible to reliably collect extensive data on the use of antidiabetic drugs during the hospital stay and after hospital discharge T A B L E 3 Association between the use versus no use of dipeptidyl peptidase-4 (DPP-4) inhibitors and outcomes estimated in logistic regression models weighted by patients' inverse probability of treatment (n = 2449, imputed sample) pandemic and they should not be discontinued.

We thank the sponsor of the study (Délégation à la Recherche 

The peer review history for this article is available at https://publons. com/publon/10.1111/dom.14324.

No sharing of participant data is allowed by our regulatory authorities.

So far, French regulations have not validated deidentified data or avatar for data sharing. Our statement might be modified in case French law changes. We will be happy to share study protocol, SAP and infor- Any proposal for collaboration requires examination by the scientific committee and the sponsor (CHU Nantes). A structured application

proposal for collaboration will be available on request.

RR reports grants, personal fees and non-financial support from

PD reports personal fees and non-financial support from

MP reports grants, non-financial support or personal fees from Air Liquid

Novo Nordisk, Orkyn, Pfizer, Sanofi, Servier and Vitalaire. PF reports non-financial support or personal fees from Astra Zeneca

PS reports non-financial support or personal fees from Novo Nordisk

SH reports grants, non-financial support or personal fees from Air Liquid

Regeneron and Sanofi. The other authors had nothing to disclose. AUTHOR CONTRIBUTIONS BC and RR had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis

Aurélie Carlier

Samy Hadjadj

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

Modulation of hematopoietic chemokine effects in vitro and in vivo by DPP-4/CD26

Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4

Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus

Coronavirus infections and type 2 diabetes -shared pathways with therapeutic implications

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

COVID-19: Is there a link between the course of infection and pharmacological agents in diabetes?

Pre-and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection

Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus

DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials

Comparative safety of Dipeptidyl Peptidase-4 inhibitors versus sulfonylureas and other glucose-lowering therapies for three acute outcomes

Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

Exposure to dipeptidylpeptidase 4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORO-NADO study

Mice: multivariate imputation by chained equations in R

Effects of adjusting for instrumental variable on bias and precision of effect estimates

Balancing covariates via propensity score weighting

PSW: propensity score weighting methods for dichotomous treatments. R package version 1.1-3

Hazard ratio Estimation using Cox Model Weighted by the Estimated Propensity Score

Elegant Graphics for Data Analysis

Treatment of type 2 diabetes in France: more dynamic than inert; analysis of prescription data for 847,122 patients

Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi database study

Exposure to dipeptidylpeptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: retrospective cohort study and meta-analysis

Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicentre, case-control, retrospective, observational study

Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an academic hospital in Lombardy

The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea

Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: a large case-control study

DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by COVID-19 -a therapeutic approach of choice in type 2 diabetic patients?

Reduced COVID-19 mortality with sitagliptin treatment? Weighing the dissemination of potentially lifesaving findings against the assurance of high scientific standards

The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies

Propensity scores based methods for estimating average treatment effect and average treatment effect among treated: a comparative study

Additional supporting information may be found online in the Supporting Information section at the end of this article.